DK0951481T3 - Anvendelse af stoffer med immunomodulatorisk virkning til behandling af amyotrofisk lateralsklerose - Google Patents

Anvendelse af stoffer med immunomodulatorisk virkning til behandling af amyotrofisk lateralsklerose

Info

Publication number
DK0951481T3
DK0951481T3 DK97951843T DK97951843T DK0951481T3 DK 0951481 T3 DK0951481 T3 DK 0951481T3 DK 97951843 T DK97951843 T DK 97951843T DK 97951843 T DK97951843 T DK 97951843T DK 0951481 T3 DK0951481 T3 DK 0951481T3
Authority
DK
Denmark
Prior art keywords
receptors
immunoglobulins
gamma
bind
lateral sclerosis
Prior art date
Application number
DK97951843T
Other languages
English (en)
Inventor
Walter Dr Schubert
Original Assignee
Mpb Meltec Patent Und Beteilig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19723690A external-priority patent/DE19723690A1/de
Application filed by Mpb Meltec Patent Und Beteilig filed Critical Mpb Meltec Patent Und Beteilig
Application granted granted Critical
Publication of DK0951481T3 publication Critical patent/DK0951481T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97951843T 1997-06-05 1997-12-10 Anvendelse af stoffer med immunomodulatorisk virkning til behandling af amyotrofisk lateralsklerose DK0951481T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19723690A DE19723690A1 (de) 1996-06-05 1997-06-05 Verwendung von Substanzen mit immunmodulatorischer Wirkung für die Behandlung der amyotrophen Lateralsklerose
PCT/DE1997/002883 WO1999029731A1 (de) 1997-06-05 1997-12-10 Verwendung von substanzen mit immunmodulatorischer wirkung für die behandlung der amyotrophen lateralsklerose

Publications (1)

Publication Number Publication Date
DK0951481T3 true DK0951481T3 (da) 2005-03-21

Family

ID=25962943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97951843T DK0951481T3 (da) 1997-06-05 1997-12-10 Anvendelse af stoffer med immunomodulatorisk virkning til behandling af amyotrofisk lateralsklerose

Country Status (7)

Country Link
EP (1) EP0951481B1 (da)
JP (1) JP2001511821A (da)
AT (1) ATE283290T1 (da)
DK (1) DK0951481T3 (da)
ES (1) ES2234038T3 (da)
PT (1) PT951481E (da)
WO (1) WO1999029731A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
EP2766482B1 (en) 2011-10-11 2016-12-07 The Brigham and Women's Hospital, Inc. Micrornas in neurodegenerative disorders
DE102016103562A1 (de) * 2015-09-17 2017-03-23 Topos Nomos Ltd. Pharmazeutische Wirkstoffe zur Verwendung in der Behandlung von Amyotropher Lateralsklerose (ALS) und Diagnoseverfahren
DE102016106510A1 (de) * 2016-04-08 2017-10-12 ToposNomos Ltd. Verfahren und Vorrichtung zum extrakorporalen Entfernen von pathogenen und/oder überzähligen Bestandteilen aus einer Zellprobe eines Patienten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655269B1 (fr) * 1989-12-01 1994-02-11 Curie Universite Pierre Marie Proteines empechant l'interaction entre un fragment fc d'une immunoglobuline et son recepteur et utilisation en therapeutique, notamment dans le traitement des affections liees aux virus hiv.
FR2702481B1 (fr) * 1993-03-09 1995-04-28 Roussel Uclaf Nouveaux récepteurs Fc-gamma III humains solubles, leur procédé de préparation, les compositions pharmaceutiques les contenant, leur application comme médicaments et leur application diagnostique.
DE19723690A1 (de) * 1996-06-05 1998-03-26 Schubert Walter Dr Md Verwendung von Substanzen mit immunmodulatorischer Wirkung für die Behandlung der amyotrophen Lateralsklerose

Also Published As

Publication number Publication date
JP2001511821A (ja) 2001-08-14
EP0951481A1 (de) 1999-10-27
WO1999029731A1 (de) 1999-06-17
ATE283290T1 (de) 2004-12-15
ES2234038T3 (es) 2005-06-16
EP0951481B1 (de) 2004-11-24
PT951481E (pt) 2005-04-29

Similar Documents

Publication Publication Date Title
Billiau Gamma-interferon: the match that lights the fire?
Lubeck et al. The interaction of murine IgG subclass proteins with human monocyte Fc receptors.
RU2220980C2 (ru) Химерное антитело, которое связывается с cd40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного т-клетками (варианты), способ лечения больного от заболевания, опосредованного т-клетками (варианты)
US4676980A (en) Target specific cross-linked heteroantibodies
Taylor Antibody therapy for rheumatoid arthritis
Zhang et al. Generation of rituximab polymer may cause hyper-cross-linking–induced apoptosis in non-Hodgkin's lymphomas
ATE454124T1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
WO2005059106A3 (en) Interferon alpha antibodies and their uses
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
SG165161A1 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
ATE477273T1 (de) Humanisierte antikoerper gegen gamma-interferon
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
ATE348632T1 (de) Prion protein peptide und deren verwendung
DK1331944T3 (da) Anvendelse af CD28-specifikke monoklonale antistoffer til stimulering af blodlegemer, der ikke bærer CD28
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
Gorovits et al. Current considerations on characterization of immune response to multi-domain biotherapeutics
PT1200126E (pt) Utilização de anticorpos monoclonais específicos de cd28 para a preparação de uma composição farmacêutica para o tratamento de infecções virais
Kürschner et al. Construction, purification, and characterization of new interferon gamma (IFN gamma) inhibitor proteins. Three IFN gamma receptor-immunoglobulin hybrid molecules.
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
DK0951481T3 (da) Anvendelse af stoffer med immunomodulatorisk virkning til behandling af amyotrofisk lateralsklerose
DE69630682D1 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
Penichet et al. Antibody-IL-2 fusion proteins: a novel strategy for immune potentiation
WO2004100882A3 (en) Inhibition of drug binding to serum albumin
Fernandes et al. Neutralization of bothropic and crotalic venom toxic activities by IgG (T) and IgGa subclasses isolated from immune horse serum